Puma Biotech (PBYI) – Major News
-
Puma Biotech (PBYI) Tops Q4 EPS by 1c, offers outlook
-
Puma Biotech (PBYI) Tops Q3 EPS by 10c; Offers FY23 Revenue Guidance
-
Puma Biotech (PBYI) Tops Q2 EPS by 9c ; Offers Guidance
-
Puma Biotech (PBYI) Tops Q1 EPS by 17c
-
Puma Biotech (PBYI) Misses Q4 EPS by 12c; Offers Guidance
-
Puma Biotech (PBYI) Tops Q4 EPS by 31c
-
Puma Biotech (PBYI) Tops Q2 EPS, Revenues Miss
-
Puma Biotech (PBYI) Tops Q4 EPS by 15c
-
Puma Biotech (PBYI) Tops Q2 EPS by 65c, Revenues Miss
-
Puma Biotech (PBYI) Tops Q1 EPS by 53c, Revenues Beat
-
Puma Biotech (PBYI) Reports Q4 EPS of $0.01
-
Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss
-
Puma Biotech (PBYI) Tops Q2 EPS by 43c
-
Puma Biotech (PBYI) Tops Q1 EPS by 89c
-
Puma Biotech (PBYI) Misses Q4 EPS by 3c
-
Puma Biotech (PBYI) Reports Q3 EPS of $0.17
-
Puma Biotech (PBYI) Tops Q2 EPS by 9c
-
Puma Biotech (PBYI) Tops Q1 EPS by 24c
-
Puma Biotech (PBYI) Tops Q4 EPS by 95c, Beat on Revenues
-
Puma Biotech (PBYI) Tops Q3 EPS by 113c
-
Puma Biotech's (PBYI) Neratinib Receives FDA Approval for Extended Adjuvant Treatment of Early Stage HER2-positive Breast Cancer
-
Puma Biotech (PBYI) Confirms FDA AdCom Backing for Neratinib
-
Puma Biotech's (PBYI) Neratinib Wins Backing From FDA Panel
-
Puma Biotech (PBYI) AdCom Meeting for Neratinib Scheduled for May 24
-
Puma Biotech (PBYI) Posts Q2 adj.-Loss of $1.17/Share
-
Puma Biotech (PBYI) Tops Q1 EPS Views
-
Puma Biotech (PBYI) Reports Q4 Loss of $1.23/Share
-
Puma Biotech (PBYI) Announces Three-Year DFS Data from PB272 Phase 3 as Adjuvnant Breast Cancer Treatment
-
Puma Biotech (PBYI) Reports Q2 Loss of $1.13
-
Puma Biotech (PBYI) Announces Statistically Significant Data from PB272 Phase 3 in Breast Cancer
-
Puma Biotechnology, Inc. (PBYI) Posts Q2 Loss of $1.05/Share
-
Puma Biotechnology (PBYI) Surges Over 200% on Statistically Significant Phase III PB272, Amended Licensing Deal with Pfizer
-
Puma Biotechnology, Inc. (PBYI) Posts Q4 Loss of 46c/Share
-
Puma Biotechnology, Inc. (PBYI) Reports Q4 Loss of 25c
-
Puma Biotechnology, Inc. (PBYI) Reports Q3 Loss of $1.29
Back to PBYI Stock Lookup